IXICO Plc (LON:IXI) said its TrialTracker technology will be used in a phase II clinical trial of a treatment for people with mild cognitive impairment caused by Alzheimer's disease.
The digital platform will be used collate both positron emission tomography (PET) and MRI scans from centres across Europe.
This data will be then assessed using IXICO's image analysis system, which has been customised to evaluate patient eligibility, assess target engagement and quantify drug effects in Alzheimer's patients.
The trial is being run by Araclon Biotech and is designed to establish the dosage regimen, as well as confirm the safety and tolerability data obtained in phase I.
IXICO chief executive Giulio Cerroni said: "We are delighted to be working with Araclon which continues our success in providing our customers with a solution that spans both PET and MR imaging services.
“It is a great example of IXICO's growing value to the biopharmaceutical industry and reinforces our confidence in revenue growth this financial year."